A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome

Jason D. Christie*, Steven Vaslef, Philip K. Chang, Addison K. May, Scott R. Gunn, Shuying Yang, Kelly Hardes, Lesley Kahl, William M. Powley, David A. Lipson, Andrew I. Bayliffe, Aili L. Lazaar

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Fingerprint

Dive into the research topics of 'A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome'. Together they form a unique fingerprint.

Medicine & Life Sciences